ABP - Abpro Holdings, Inc.

0.522
-0.278   -53.276%

Share volume: 3,258,991
Last Updated: 02-20-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.44%

PREVIOUS CLOSE
CHG
CHG%
$0.80
-0.28
-0.35%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
30%
Profitability 35%
Dept financing 43%
Liquidity 2%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
-65.20%
3 Months
-91.02%
6 Months
142.79%
1 Year
-5.09%
2 Year
-21.49%
Key data
Stock price
$0.52
P/E Ratio 
0.00
DAY RANGE
$0.52 - $0.78
EPS 
-$0.71
52 WEEK RANGE
$0.15 - $7.34
52 WEEK CHANGE
-$1.75
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
2.716 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
$7,754,990
Company detail
CEO: Jin Wook Suk and Ian Chan
Region: US
Website: abpro.com
Employees: 15
IPO year: 2022
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Abpro Holdings, Inc., a biotechnology company, provides antibody therapeutics for cancer related issues. Its platform DiversImmune addresses the antibody therapeutics. The company's product candidates include ABP-102 for the treatment of breast and gastric cancer; and ABP-110 for the treatment of liver cancer. It also offers ABP-105 for the treatment of gastric cancer and ABP 201 for vascular diseases of the eye and diabetic macular edema. Abpro Holdings, Inc. was incorporated in 2004 and is based in Woburn, Massachusetts.

Recent news